Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑&gamma; in non‑small cell lung cancer

Wang,Yongming; Wang,Weiyu; Wang,Huaijie; Qin,Liya; Zhang,Meijia; Zhang,Yong; Wang,Yubing; Hao,Changcheng; Qu,Meihua; Wang,Gongchao

doi:10.3892/ol.2024.14392

Clinical prognostic significance of xeroderma pigmentosum group C and IFN‑γ in non‑small cell lung cancer

Authors:
- Yongming Wang
- Weiyu Wang
- Huaijie Wang
- Liya Qin
- Meijia Zhang
- Yong Zhang
- Yubing Wang
- Changcheng Hao
- Meihua Qu
- Gongchao Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Thoracic Surgery, Translational Medical Center, Weifang Second People's Hospital (Weifang Respiratory Disease Hospital), Weifang, Shandong 261041, P.R. China, Biopharmaceutical Laboratory, Key Laboratory of Shandong Province Colleges and Universities, School of Life Sciences and Technology, Weifang Medical University, Weifang, Shandong 261053, P.R. China
Published online on: April 9, 2024 https://doi.org/10.3892/ol.2024.14392
Article Number: 259
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the most common cancer in the world due to its high incidence and recurrence. Genetic instability is one of the main factors leading to its occurrence, development and poor prognosis. Decreased xeroderma pigmentosum group C (XPC) expression notably enhances the stem cell properties of lung cancer cells and increases their proliferation and migration. Additionally, patients with lung cancer and low XPC expression had a poor prognosis. The purpose of the present study was to analyze the effect of XPC and IFN‑γ on the clinical prognosis of patients with non‑small cell lung cancer (NSCLC). Lung adenocarcinoma specimens were collected from a total of 140 patients with NSCLC. Additionally, from these 140 patients, 48 paracarcinoma tissue specimens were also collected, which were later used to construct tissue microarrays. The expression of XPC and IFN‑γ in cancer tissues and in paraneoplastic tissues was detected using immunohistochemistry. The prognosis and overall survival of patients were determined through telephone follow‑up. The results showed a positive correlation between expression of XPC and IFN‑γ in NSCLC. Additionally, high expression of both markers was associated with a favorable prognosis in patients with NSCLC. The aforementioned findings suggest that the expression of XPC and IFN‑γ has prognostic value in clinical practice and is expected to become a marker for clinical application.

View Figures

View References

1	Wu F, Wang L and Zhou C: Lung cancer in China: Current and prospect. Curr Opin Oncol. 33:40–46. 2021. View Article : Google Scholar : PubMed/NCBI
2	Bade BC and Dela Cruz CS: Lung Cancer 2020: Epidemiology, etiology, and prevention. Clin Chest Med. 41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
3	Shell SM, Hawkins EK, Tsai MS, Hlaing AS, Rizzo CJ and Chazin WJ: Xeroderma pigmentosum complementation group C protein (XPC) serves as a general sensor of damaged DNA. DNA Repair (Amst). 12:947–953. 2013. View Article : Google Scholar : PubMed/NCBI
4	Zhou H, Saliba J, Sandusky GE and Sears CR: XPC protects against smoking- and carcinogen-induced lung adenocarcinoma. Carcinogenesis. 40:403–411. 2019. View Article : Google Scholar : PubMed/NCBI
5	Kobaisi F, Sulpice E, Barette C, Fayyad N, Fauvarque MO, Badran B, Fayyad-Kazan M, Fayyad-Kazan H, Gidrol X and Rachidi W: Isoconazole and clemizole hydrochloride partially reverse the xeroderma pigmentosum C phenotype. Int J Mol Sci. 22:81562021. View Article : Google Scholar : PubMed/NCBI
6	D'Errico M, Parlanti E, Teson M, de Jesus BM, Degan P, Calcagnile A, Jaruga P, Bjørås M, Crescenzi M, Pedrini AM, et al: New functions of XPC in the protection of human skin cells from oxidative damage. EMBO J. 25:4305–4315. 2006. View Article : Google Scholar : PubMed/NCBI
7	Fayyad N, Kobaisi F, Beal D, Mahfouf W, Ged C, Morice-Picard F, Fayyad-Kazan M, Fayyad-Kazan H, Badran B, Rezvani HR and Rachidi W: Xeroderma pigmentosum C (XPC) mutations in primary fibroblasts impair base excision repair pathway and increase oxidative DNA damage. Front Genet. 11:5616872020. View Article : Google Scholar : PubMed/NCBI
8	Wang W, Ma S, Ding Z, Yang Y, Wang H, Yang K, Cai X, Li H, Gao Z and Qu M: XPC protein improves lung adenocarcinoma prognosis by inhibiting lung cancer cell stemness. Front Pharmacol. 12:7079402021. View Article : Google Scholar : PubMed/NCBI
9	Zhang X, He N, Gu D, Wickliffe J, Salazar J, Boldogh I and Xie J: Genetic Evidence for XPC-KRAS interactions during lung cancer development. J Genet Genomics. 42:589–596. 2015. View Article : Google Scholar : PubMed/NCBI
10	Abolfathi H, Sheikhpour M, Shahraeini SS, Khatami S and Nojoumi SA: Studies in lung cancer cytokine proteomics: A review. Expert Rev Proteomics. 18:49–64. 2021. View Article : Google Scholar : PubMed/NCBI
11	Marrugal A, Ojeda L, Paz-Ares L, Molina-Pinelo S and Ferrer I: Proteomic-Based approaches for the study of cytokines in lung cancer. Dis Markers. 2016:21386272016. View Article : Google Scholar : PubMed/NCBI
12	Gao Y, Yang J, Cai Y, Fu S, Zhang N, Fu X and Li L: IFN-ү-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J Cancer. 143:931–943. 2018. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning W, Zeng H, Zhang N, Du W, Chen C and Huang JA: PD-L1 induced by IFN-ү from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 22:1026–1033. 2017. View Article : Google Scholar : PubMed/NCBI
14	Fang C, Weng T, Hu S, Yuan Z, Xiong H, Huang B, Cai Y, Li L and Fu X: IFN-ү-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells. Oncoimmunology. 10:19625912021. View Article : Google Scholar : PubMed/NCBI
15	Nasim F, Sabath BF and Eapen GA: Lung cancer. Med Clin North Am. 103:463–473. 2019. View Article : Google Scholar : PubMed/NCBI
16	Kgokolo MCM, Anderson K, Siwele SC, Steel HC, Kwofie LLI, Sathekge MM, Meyer PWA, Rapoport BL and Anderson R: Elevated levels of soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and systemic inflammatory stress as potential contributors to immune suppression and generalized tumorigenesis in a cohort of South African xeroderma pigmentosum patients. Front Oncol. 12:8197902022. View Article : Google Scholar : PubMed/NCBI
17	Wu YH, Wu TC, Liao JW, Yeh KT, Chen CY and Lee H: p53 dysfunction by xeroderma pigmentosum group c defects enhance lung adenocarcinoma metastasis via increased Mmp1 expression. Cancer Res. 70:10422–10432. 2010. View Article : Google Scholar : PubMed/NCBI
18	Ahn SS, Kwon M, Sung M, Jung SM, Lee SW, Park YB, Kim ST and Song JJ: Ex Vivo Interferon gamma production by peripheral immune cells predicts survival in lung adenocarcinoma. Clin Lung Cancer. 20:e299–e308. 2019. View Article : Google Scholar : PubMed/NCBI
19	Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, et al: Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Rep. 34:1087842021. View Article : Google Scholar : PubMed/NCBI
20	Akoglu H: User's guide to correlation coefficients. Turk J Emerg Med. 18:91–93. 2018. View Article : Google Scholar : PubMed/NCBI
21	Asamura H, Nishimura KK, Giroux DJ, Chansky K, Hoering A, Rusch V and Rami-Porta R; Members of the IASLC Staging and Prognostic Factors Committee of the Advisory Boards, and Participating Institutions, : IASLC lung cancer staging project: The new database to inform revisions in the Ninth Edition of the TNM classification of lung cancer. J Thorac Oncol. 18:564–575. 2023. View Article : Google Scholar : PubMed/NCBI
22	Villalobos P and Wistuba II: Lung cancer biomarkers. Hematol Oncol Clin North Am. 31:13–29. 2017. View Article : Google Scholar : PubMed/NCBI
23	Gao C, Kong N, Zhang F, Zhou L, Xu M and Wu L: Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. BMC Bioinformatics. 23:3272022. View Article : Google Scholar : PubMed/NCBI
24	Ruiz-Cordero R and Devine WP: Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 13:17–33. 2020. View Article : Google Scholar : PubMed/NCBI
25	Rodriguez-Canales J, Parra-Cuentas E and Wistuba II: Diagnosis and molecular classification of lung cancer. Cancer Treat Res. 170:25–46. 2016. View Article : Google Scholar : PubMed/NCBI
26	Luo C, Lei M and Zhang Y, Zhang Q, Li L, Lian J, Liu S, Wang L, Pi G and Zhang Y: Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. J Cell Mol Med. 24:1233–1244. 2020. View Article : Google Scholar : PubMed/NCBI
27	Lundin A and Driscoll B: Lung cancer stem cells: Progress and prospects. Cancer Lett. 338:89–93. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sugasawa K: XPC: Its Product and Biological Roles. Molecular Mechanisms of Xeroderma Pigmentosum. Advances in Experimental Medicine and Biology. Ahmad SI and Hanaoka F: Volume 637. Springer; New York, NY: 2008, PubMed/NCBI
29	Nemzow L, Lubin A, Zhang L and Gong F: XPC: Going where no DNA damage sensor has gone before. DNA Repair (Amst). 36:19–27. 2015. View Article : Google Scholar : PubMed/NCBI
30	Cui T, Srivastava AK, Han C, Yang L, Zhao R, Zou N, Qu M, Duan W, Zhang X and Wang Q-E: XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression. Oncotarget. 6:10060–10072. 2015. View Article : Google Scholar : PubMed/NCBI
31	Teng X, Fan XF, Li Q, Liu S, Wu DY, Wang SY, Shi Y and Dong M: XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Oncol Rep. 41:1875–1882. 2019.PubMed/NCBI
32	Nasrallah NA, Wiese BM and Sears CR: Xeroderma pigmentosum complementation group C (XPC): Emerging roles in non-dermatologic malignancies. Front Oncol. 12:8469652022. View Article : Google Scholar : PubMed/NCBI
33	Medler TR, Murugan D, Horton W, Kumar S, Cotechini T, Forsyth AM, Leyshock P, Leitenberger JJ, Kulesz-Martin M, Margolin AA, et al: Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy. Cancer Cell. 34:561–578.e6. 2018. View Article : Google Scholar : PubMed/NCBI
34	Weichselbaum RR, Liang H, Deng L and Fu YX: Radiotherapy and immunotherapy: A beneficial liaison? Nat Rev Clin Oncol. 14:365–379. 2017. View Article : Google Scholar : PubMed/NCBI
35	Burke F, East N, Upton C, Patel K and Balkwill FR: Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: Enhancement of effect by batimastat. EJC. 33:1114–1121. 1997. View Article : Google Scholar : PubMed/NCBI
36	Schoenborn JR and Wilson CB: Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 96:41–101. 2007.PubMed/NCBI
37	Shin EC, Ahn JM, Kim CH, Choi Y, Ahn YS, Kim H, Kim SJ and Park JH: IFN-gamma induces cell death in human hepatoma cells through a TRAIL/death receptor-mediated apoptotic pathway. Int J Cancer. 93:262–268. 2001. View Article : Google Scholar : PubMed/NCBI
38	Minn AJ and Wherry EJ: Combination cancer therapies with immune checkpoint blockade: Convergence on interferon signaling. Cell. 165:272–275. 2016. View Article : Google Scholar : PubMed/NCBI
39	Galani V, Kastamoulas M, Varouktsi A, Lampri E, Mitselou A and Arvanitis DL: IFNs-signaling effects on lung cancer: An up-to-date pathways-specific review. Clin Exp Med. 17:281–289. 2017. View Article : Google Scholar : PubMed/NCBI
40	Lee KS, Chung WY, Park JE, Jung YJ, Park JH, Sheen SS and Park KJ: Interferon-ү-Inducible chemokines as prognostic markers for lung cancer. Int J Environ Res Public Health. 18:93452021. View Article : Google Scholar : PubMed/NCBI
41	Song M, Ping Y, Zhang K, Yang L, Li F, Zhang C, Cheng S, Yue D, Maimela NR, Qu J, et al: Low-Dose IFNү induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer. Cancer Res. 79:3737–3748. 2019. View Article : Google Scholar : PubMed/NCBI